Fosun Pharma

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 
 Based in Hong Kong, Insilico Medicine focuses on three areas of drug discovery and development: disease target identification, generation of synthetic biology and novel molecules data, and predicting clinical trial outcomes.&nbsp;
 
 
 The company's key focus area is anti-aging interventions; however, there is also a therapeutic focus on areas such as oncology, dermatology, metabolic diseases, neuroscience, and rare diseases. Nearly a quarter of the company&rsquo;s R&amp;D budget is committed toward aging-related diseases.&nbsp;
 
 
 The company collaborates with pharma companies and also has its own pipeline of small molecules targeting many disease areas, which the company aims to license to pharma players later.&nbsp;
 
 
 In a landmark achievement, Insilico announced in November 2021 that it initiated its first in-human clinical trial of its lead drug compound ISM001-055 (INS018_055) for idiopathic pulmonary fibrosis (IPF). It is reportedly the first-ever AI-discovered drug to be tested on a human. Two years earlier, the company announced that the compound was discovered by the company&rsquo;s AI platform in just 46 days compared to the two- to three-year timespan required for traditional drug discoveries. It also completed the entire preclinical stage, from the earliest stages of identifying potential targets, in a record time of 18 months. In February 2023, the candidate became the first to receive an 
 <a href="https://www.genengnews.com/artificial-intelligence/insilico-gains-fdas-first-orphan-drug-designation-for-ai-candidate/">
 orphan drug designation
 </a>
 from the FDA and initiated a global 
 <a href="https://sp-edge.com/updates/19798">
 Phase II clinical trial
 </a>
 in June 2023.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company entered partnerships with several China- and US-based companies, including NVIDIA (May 2024) to launch the Nach0 language processing tool for biomedical and chemical tasks; 
 <a href="https://sp-edge.com/updates/28807">
 InvoX Pharma
 </a>
 (April 2024) to identify potential uses for invoX&rsquo;s pipeline using Insilico&rsquo;s PandaOmics AI platform; 
 <a href="https://sp-edge.com/updates/21805">
 Exelixis
 </a>
 (September 2023) to develop and commercialize an AI-generated cancer treatment, ISM3091; 
 <a href="https://en.prnasia.com/story/archive/3487576_AE87576_0?utm_source=cleartime-customer&utm_medium=email&fbclid=IwAR3GoL4_NIvdPGv5a-d7QgZkNh9pgJSKYzbFawltIe3Jv17rn1ca72ARUR0">
 4B Technologies
 </a>
 (August 2021) to develop innovative small-molecule therapies for neurological diseases; 
 <a href="https://www.prnewswire.com/news-releases/insilico-medicine-announces-an-ai-driven-protac-rd-collaboration-with-arvinas-301351106.html?tc=eml_cleartime&fbclid=IwAR0AQIMqXebdleapMxubR0OqkkSll_CnglrSUa2TuRWXbXliLoHZGOdQRrE">
 Arvinas
 </a>
 (August 2021) to demonstrate the potential of combining AI with proteolysis-targeting chimera (PROTACs); 
 <a href="https://www.eurekalert.org/news-releases/777014">
 Teva Branded Pharmaceutical
 </a>
 (June 2021); and 
 <a href="https://www.eurekalert.org/news-releases/532850">
 APRINOIA Therapeutics
 </a>
 (December 2020).
 
 
 In January 2022, insilico collaborated with 
 <a href="https://www.prnewswire.com/news-releases/fosun-pharma-and-insilico-medicine-announce-a-strategic-ai-driven-drug-discovery-and-development-collaboration-to-jointly-advance-multiple-targets-301457569.html?tc=eml_cleartime">
 Fosun Pharma
 </a>
 to use AI technology in drug discovery and development. The companies completed the second preclinical candidate compound (PCC) for treating solid tumors in 
 <a href="https://sp-edge.com/updates/31232">
 July 2024
 </a>
 .
 
 
 The company also collaborated with big pharma companies 
 <a href="https://www.eurekalert.org/news-releases/490685">
 Pfizer
 </a>
 (January 2020) to utilize Insilico's machine-learning technology and proprietary Pandomics Discovery Platform and 
 <a href="https://sp-edge.com/updates/14409">
 Sanofi 
 </a>
 (November 2022) to develop novel therapeutics across six new targets.
 
</div>

Novel therapies to reboot cells and organs

Cell & Gene Therapy

Gyroscope Therapeutics is a gene therapy company focused on developing treatments for ocular diseases, particularly age-related macular degeneration (AMD). The company's lead candidate, GT005, is an investigational gene therapy designed to treat geographic atrophy (GA), an advanced form of dry AMD that leads to progressive and irreversible vision loss. GT005 aims to increase complement factor I (CFI) levels in the retina to regulate inflammation and slow disease progression. It utilizes an adeno-associated viral vector (AAV) to enhance CFI expression and is administered as a one-time treatment delivered under the retina. As of 2023, GT005 was undergoing Phase I and II clinical trials.Gyroscope combines discovery, research, drug development, manufacturing capabilities, and surgical delivery platforms in its approach to ocular gene therapies. The company generated positive clinical data from its Phase I/II FOCUS trial for GT005. In December 2021, Novartis agreed to acquire Gyroscope Therapeutics for up to USD 1.5 billion, with an upfront payment of USD 800 million and potential milestone payments of up to USD 700 million. This acquisition was aimed at accelerating the development of gene therapies for ocular diseases.Key customers and partnershipsGyroscope Therapeutics was founded in 2016 and grew to a team of nearly 200 employees by 2021. The company has roots in academic research, with its initial intellectual property coming from Professor Sir Peter Lachmann's work, which was supported by Cambridge Enterprise since 2009. Gyroscope received backing from various investors, including Syncona, which was a founding investor, and Cambridge Innovation Capital, which participated in the company's GBP 50.4 million Series B funding round in September 2019.In February 2022, Novartis completed the acquisition of Gyroscope Therapeutics, integrating the company into its gene therapy expertise and ophthalmology commitment. This partnership aims to leverage Novartis' experience in ocular gene therapies, including its work with Luxturna for inherited retinal dystrophy patients outside the US, to further advance Gyroscope's promising treatments toward clinical use and potentially transform the lives of patients with debilitating eye diseases.

Targeting complex diseases with complex molecules

Large-molecule Therapeutics

<div>
 
 Ambrx Biopharma is a clinical-stage biopharmaceutical company that specializes in an expanded genetic code technology platform to create engineered precision biologics. These include next-generation antibody-drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines, and long-acting therapeutic peptides. The company is advancing a robust portfolio of clinical and preclinical programs across multiple therapeutic areas, with a focus on optimizing efficacy, safety, and ease of use.
 
 
 
 
 Ambrx's lead product candidate is ARX788, a HER2-directed ADC for metastatic HER2-positive breast cancer. Other key candidates in development include ARX517 (an ADC targeting PSMA for metastatic castration-resistant prostate cancer), ARX788 (a HER2-directed ADC for breast cancer), and ARX305 (an ADC targeting CD-70 for renal cell carcinoma). In March 2024, Ambrx was acquired by Johnson &amp; Johnson for approximately USD 2 billion, providing J&amp;J the opportunity to design, develop and commercialize targeted oncology therapeutics using Ambrx's proprietary ADC technology.
 
</div>

Bringing Life-Saving Biologics to More Patients

Biosimilars

<div>
 
 Shanghai Henlius biotech, Inc., founded in 2010, is a global biopharmaceutical company focused on developing high-quality, affordable, and innovative biologic medicines for patients worldwide. The company specializes in oncology, autoimmune diseases, and ophthalmic conditions. Henlius has established a fully integrated platform with capabilities spanning the entire biologics value chain, including research and development, manufacturing, and commercialization. As of 2024, Henlius has launched five products in China, with three approved for marketing in overseas markets. The company has received approval for 23 indications worldwide and has three marketing applications under review in China and the EU, respectively.
 
 
 
 
 Henlius has built a diverse product pipeline covering over 50 molecules, with a particular focus on immuno-oncology combination therapies. The company's flagship product, HANSIZHUANG (serplulimab injection), is an innovative anti-PD-1 monoclonal antibody approved for multiple indications, including MSI-H solid tumors, squamous non-small cell lung cancer, extensive-stage small cell lung cancer, and esophageal squamous cell carcinoma. Notably, HANSIZHUANG became the world's first anti-PD-1 mAb approved for first-line treatment of small cell lung cancer. Other key products include HANLIKANG (rituximab), China's first approved biosimilar, and HANQUYOU (trastuzumab), a biosimilar approved in China, Europe, and the US. Henlius has established global innovation centers and Shanghai-based commercial manufacturing facilities certified by China, EU, and US GMP standards. The company's integrated platform enables high-titer cell line development, proprietary cell culture production, and continuous manufacturing processes.
 
 
 
 
 Key customers and partnerships
 
 
 
 
 
 Henlius has established partnerships with global pharmaceutical companies to expand its reach outside China. The company has collaborated with Accord healthcare, Biosidus S.A., Cipla, and The Jacobson Group to bring its therapeutics to patients across the Americas, Asia, and Europe. In September, Henlius entered into a collaboration agreement with PT Kalbe Genexine Biologics (KGBio), granting exclusive rights to develop and commercialize HLX10 in the Philippines, Indonesia, and eight other Southeast Asian countries. Within China, Henlius has adopted an independent commercialization strategy, leveraging support from its parent company, Fosun Pharma. The company has conducted over 30 clinical studies for 16 products globally, expanding its presence in major markets as well as emerging markets.
 
 
 
</div>

Fosun Kite Biotechnology develops immune cell therapy products. Fosun Kite Biotechnology is a joint venture of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, and U.S. Kite Pharma.

Located in Baltimore, Maryland, VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection. This strategy utilizes a proprietary tumor-specific, tumor type agnostic, virus-inspired platform termed Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs) that redirects pre-existing pathogenic or childhood vaccine immune memory towards tumors.

Bianjie.AI specializes in research on blockchain product technology, application platform development, and solution consulting.

Scolioscan focuses on medical imaging technology research & development, self-service production and technology distribution and promotion.

Primelink Bio is a Biotechnology firm that is working to to develop next generation of drug delivery systems.

Porton Advanced Solutions (Porton Advanced) is a CDMO specializing in Cell and Gene Therapy (CGT). To address clients' therapeutic product demands at the pre-clinical, clinical, and commercial stages, the firm offers end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services.

Fosun Xingmai is a scientific and technological innovation-oriented enterprise focusing on the research and development, production and sales of medical imaging and pathological artificial intelligence software and digital solutions. Its products mainly analyze medical images through the use of artificial intelligence technology.

ZuriMED Technologies AG is an innovative Swiss-based startup that spun off from the University of Zurich and ETH Zurich and dedicated to pioneering advancements in sports medicine through the development of cutting-edge medical technologies for soft tissue repair.  The Surgical-Fiberlock technology, developed by ZuriMED, is a breakthrough in the surgical repair of soft tissues. It functions like a surgical “sewing” machine, mechanically “interlocking” the medical patch fibers into soft tissue, allowing the surgeon to attach patches in an easier, faster, and more reliable way for various clinical applications.

Yuesai Biotechnology is a cell therapy drug developer that uses human pluripotent stem cell technology. Yuesai Biotechnology develops stem cell therapy for neurodegenerative diseases, rare diseases, and tumors using its proprietary intellectual property rights of human pluripotent stem cell preparation, cultivation, differentiation, and gene editing technology platform.

UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders.

Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and, unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

Jianjia Robot develops a hard tissue surgical robot platform promoting technological progress in the field of surgery at home and abroad. Jianjia Robot's orthopedic joint surgical robot, ARTHROBOT, can cover both hip and knee joints, breaking the long-term monopoly of imported surgical robots in this field.

Gyroscope is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye. The company explores the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD), and gene therapy as a mode of treatment delivery. Its lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. GT005 is designed to restore balance to an overactive complement system by increasing the production of the Complement Factor I protein. GT005 is currently being evaluated in a Phase I/II clinical trial called FOCUS and Phase II clinical trials called EXPLORE and HORIZON. Andrew Lotery, David Kavanagh, and Peter Lachmann co-founded Gyroscope Therapeutics in Stevenage, Herefordshire in 2016.

MitrAssist introduces a minimally invasive approach to MR treatment. Its mitral valve implant works in unison with the natural mitral valve without harming its functionality.  MitrAssist has developed a new approach to treating MR that is neither repair nor replacement. Instead, its proprietary valve implant is placed on top of the natural valve to work in unison with it and to enhance valve functionality.  MitrAssist’s “valve-in-valve” approach overcomes the various challenges of MR and offers an improved treatment solution for all MR patients. It has significant advantages over minimally invasive solutions – both existing and in development.

Hinova Pharma is an innovative drug research and development manufacturer that provides users with compound HC-1119 androgen receptor (AR) antagonism by using drug discovery systems such as medicinal chemistry, biological screening, process research, quality research, clinical reporting, and clinical research. Drugs, HC-1102 androgen receptor inhibitors and other products, for the treatment of advanced prostate cancer and breast cancer.

Yudo Bio provides biopharmaceutical products. It has its headquarters in Shanghai in China.

EOS imaging is a medical company revolutionizing the treatment continuum for the most common osteoarticular conditions (hip, knee and spine) and associated orthopedic surgeries.  Its EOS® 2D/3D imaging system is specifically adapted to the needs of orthopedic surgeons and radiologists. This personalized imaging tool gives a precise 3D image of the patient's skeleton in the upright position that can be used to inform all aspects of care. The Company has obtained authorization to market the system in 48 countries. The Company is based in Paris, with a subsidiary in the United States in Cambridge, Massachusetts, as well as offices in Montreal (Canada) and Germany.

Glycotest Diagnostics is developing unique and non-invasive blood tests for the large populations at risk of developing liver cancers and fibrosis-cirrhosis. Our technology could revolutionize care and treatment for groups at risk due to chronic liver disease—both people with viral hepatitis (chronic hepatitis B and C infections) and the rapidly growing population with non-viral hepatitis due to obesity and metabolic disease. Over 25 million people in the US, 800 million worldwide, and another 1.2 billion in jeopardy due to fatty liver disease may benefit from Glycotest’s products.

Butterfly has created the world's first handheld, single-probe whole-body ultrasound system using its patented Ultrasound-on-Chip™ semiconductor technology. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly is paving the way for earlier detection and remote management of health conditions around the world.

Fushoukang is a home medical care services organization. They offer home medical care, nursing, and rehabilitation services. They provide long term services, institutional care, home care, smart home beds, and hospitcal escorts for the healthy self care elderly, semin disabled elderly , sick elderly, and demented elderly, and more services.

Yidebang is a Beijing-based healthcare software developer, which provides management solution, drug supply, hierarchical diagnosis and treatment and other supporting medical services for basic-level clinics in China.

Shanghai Henlius Biotech provides clinical-stage biopharmaceutical services. The company focuses on the development, production and commercialization of mAb biosimilar drugs, bio-betters, and novel mAbs using cutting-edge technology. The company is a joint venture between Shanghai Fosun Pharmaceutical and Henlius Biopharmaceuticals, formed in 2009. It is headquartered in the Shanghai Caohejing High-Technology Park.

LinkedCare is a consumer medical digital service platform that provides integrated operation and management solutions for consumer medical enterprises such as dental clinics and aesthetic medical institutions, and assists institutions in realizing management standardization, diagnosis and treatment standardization, marketing socialization, mobile office, and decision-making data standardization. LinkedCare fully automates the digital operation of consumer medical institutions, assisting them to complete the closed loop of health management that increases revenue, avoids risks, lowers expenditures, and improves efficiency.

Sinopharm Online has a pharmaceutical retail platform to provide users with online medication consultation, medical and health management consulting services, etc. The main sales cover Chinese and Western medicines and health products. , medical equipment, Chinese medicine

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788.

DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke and other vascular diseases where no current therapies are available.  The company's treatments primarily focus on on chronic kidney disease and acute ischemic stroke. Its pipeline product, DM199, is a recombinant form of human tissue kallikrein-1.

Spirosure develops breath-analysis devices to apply novel breath-based analysis in disease diagnosis and management. Their breath-analysis devices focus on providing non-invasive products for the management of chronic diseases including asthma, COPD, and chronic pulmonary hypertension using a nexus of consumer technologies for preventative healthcare through sensors and algorithms. They enable medical researchers to detect biomarkers in a patient's breath to diagnose and monitor respiratory conditions.

Yaoshibang is a Chinese B2B pharmaceutical trading platform.

Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development.

company that was founded in 2007 by a group of healthcare investors. The company has a focus on the development, manufacture and sale of high quality generic pharmaceutical products for two of the most important markets in the world…the United States and China.  Our US office is located in central New Jersey. In addition to executive management, this location also houses staff in the following functions for the US market: product and business development, finance, regulatory affairs, and commercial operations. Product development is being undertaken at various locations around the world under the supervision of its experienced R&D, quality, and regulatory leaders.

Anhui Sunhere Pharmaceutical is a manufacturer of medical and pharmaceutical products. Their products include hypromellose, carmellose calcium, hypromellose phthalate, microcrystalline cellulose, and polyacrylic resin emulsion. They also offer sales, research, and development services.

Check-Cap is a young and dynamic medical device company with breakthrough solution for Colorectal Cancer Screening. The Check-Cap device requires no bowel preparation or invasive procedures, and is expected to detect clinically significant polyps within the same range of accuracy as a standard colonoscopy.

BSC develops a series of software and hardware products. They provide teleconsultation, remote video, remote ECG, telepathology, distance education, and remote ultrasound services.

Saladax develops rapid blood tests for point-of-care and for laboratory analyzers for use in psychiatry and oncology. The firm has been supplying laboratories and clinicians worldwide with revolutionary diagnostic solutions for more than 15 years.

Golden Elephant Pharmacy is an online pharmaceutical store.

Q1 2022 founders not found Q1 2022 c-suite not found

Laoniangjiu Catering is a food and beverage company. They offer a business takeaway menu with staple meals, beverages, desserts, delicious soups, and breakfast snacks. They provide chinese-style fast food products that are mainly flavored and can be superimposed on food and beverages.

Fosun Pharma is a biopharmaceutical and healthcare industry. Fosun Pharma has captured opportunities within the rapidly developing Chinese healthcare industry as well as from the globalization of Chinese healthcare companies in general. Fosun Pharma's operations strategically cover several important segments of the healthcare industry value-chain, including: pharmaceutical manufacturing, distribution and retail.

<div> Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKEX: 02196) is a global innovation-driven pharmaceutical and healthcare industry group founded in 1994 and headquartered in Shanghai, China. <ul> </ul> Fosun Pharma directly operates businesses including: <ul> <li> Pharmaceuticals: The company's core business, focusing on innovative drugs and biosimilars in therapeutic areas like oncology, immunology, central nervous system disorders, and chronic diseases. Key products include: </li> </ul> <ul> <li> Han Si Zhuang (serplulimab): PD-1 inhibitor approved for multiple cancer indications </li> <li> Han Qu You (trastuzumab): Biosimilar for breast and gastric cancers </li> <li> Yi Kai Da: China's first approved CAR-T cell therapy </li> <li> Su Ke Xin (avatrombopag): Treatment for thrombocytopenia </li> </ul> <ul> <li> Medical Devices: Including the Da Vinci surgical robot system through joint venture Intuitive Fosun </li> </ul> <ul> <li> Medical Diagnosis </li> </ul> <ul> <li> healthcare Services </li> </ul> As of June 2024, Fosun Pharma had over 70 major pipeline projects for innovative drugs and biosimilars. The company invests heavily in R&amp;D, spending RMB 2.88 billion on R&amp;D in the first half of 2023, representing 15.75% of its pharmaceutical manufacturing revenue. Fosun Pharma has actively expanded its global presence through partnerships, acquisitions, and organic growth. The company has established businesses in over 35 countries and regions. In 2023, overseas revenue accounted for 45% of total revenue at RMB 89.2 billion. Key international markets include the US, Europe, Africa, and Southeast Asia. </div>

Fosun Pharma Announces 2024Q3 Financial Results

ANALYST_QUICK_TAKE

PROMINENT_CATEGORY

<div>
 
 Insilico Medicine, an AI-powered drug developer, has partnered with Fosun Pharma to complete the second preclinical candidate compound (PCC) for potential use as a therapeutic in the treatment of solid tumors. The compound uses a synthetic lethal strategy and is set to submit for pre-IND application by Q4 2024.
 This compound aims at DNA damage repair mechanisms, integral to tumor therapy. The development process used Insilico’s PandaOmics for target identification and Life Star 1, an AI lab, for operations. Chemistry42, another AI tool, developed compounds specifically for the target. Preclinical studies have indicated promising results for the compound, such as anti-tumor efficacy and solid ADMET properties. Fosun Pharma intends to carry forward the research and development of the compound, post its advancement to the IND-enabling stage by Insilico. 
 
</div> Analyst QuickTake : 
 The partnership between Insilico Medicine and Fosun Pharma was established in <a href="https: 
//sp-edge.com/updates/7740"> January 2022 </a> . It was aimed to develop multiple drug targets, including Insilico’s Glutaminyl-peptide cyclotransferase-like (QPCTL) program, and to develop Fosun’s internal drug development programs using Insilico's PandaOmics and Chemistry42 platforms.

Fosun Pharma

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless